Dec. 4, 2017 Price forecast | 2 weeks: -0.46% | 1 month: -0.14% | 3 months: -0.73%


CRSP stock forecast

Our latest prediction for CRISPR Therapeutics AG's stock price was made on the Dec. 4, 2017 when the stock price was at 18.26$.

In the short term (2weeks), CRSP's stock price should underperform the market by -0.46%. During that period the price should oscillate between -7.90% and +8.10%.

In the medium term (3months), CRSP's stock price should underperform the market by -0.73%. During that period the price should oscillate between -16.76% and +21.47%.

Create a solid portfolio with CRSP

Add CRSP to your portfolio and optimize it!


About CRISPR Therapeutics AG

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

At the moment the company generates 289M USD in revenues.

On its last earning announcement, the company reported a profit of 0.95$ per share.

The book value per share is 5.62$

CRISPR Therapeutics AG website


Three months stock forecastDec. 4, 2017


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
289M - 22M 7.50% 46M 0.95 - - 59M 5.62 48M -9M 40M